Đánh giá hiệu quả điều trị tổn thương tái hẹp trong Stent bằng bóng phủ thuốc chứa Paclitaxel tại Bệnh viện Tim Hà Nội

Abstract

This study evaluated the effectiveness of paclitaxel drug-coated balloon (DCB) angioplasty for the treatment of coronary in-stent restenosis (ISR) at Hanoi Heart Hospital. A prospective descriptive study was conducted on 33 patients with ISR treated with paclitaxel-coated balloon angioplasty, including clinical and angiographic follow-up at 6 and 12 months, between May 2024 and October 2025. The mean patient age was 70.75 ± 9.16 years old, and 72.7% were male. Common cardiovascular risk factors included hypertension (69.7%), dyslipidemia (54.5%), and diabetes mellitus (39.4%). The left anterior descending artery was the most frequently involved vessel (39.4%). Post-procedural angiography demonstrated a marked improvement in vessel patency, with minimal lumen diameter increasing from 0.25 ± 0.18 mm to 2.60 ± 0.50 mm and residual stenosis decreasing from 84.22% to 15.58%. TIMI 3 flow was achieved in all patients. No acute procedural complications or in-hospital deaths occurred. At 12-month follow-up, the incidence of major adverse cardiac events was 3%, corresponding to one case of target lesion revascularization. Repeat angiography performed in 10 patients identified a single case (3%) of restenosis at a bifurcation lesion. Overall, paclitaxel-coated balloon angioplasty demonstrated favorable safety and sustained clinical and angiographic outcomes in the treatment of coronary ISR.